EB
VRDN icon

Eastern Bank’s Viridian Therapeutics VRDN Stock Holding History

Eastern Bank’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-330
Closed -$6.46K – 1188
2026
Q1 		$6.46K Hold
330
– – ﹤0.01% 905
2025
Q4 		$10.3K Buy
+330
New +$9.05K ﹤0.01% 879

Other funds holding VRDN

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
EC
Eleva Capital Paris, France $343M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
LI
LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM

Eastern Bank's VRDN Position: Q2 2026 in Review

Eastern Bank sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 330 shares — an estimated $6.46K sold.

Eastern Bank first reported a position in VRDN in Q4 2025 and held it in 2 quarters. The position peaked at $10.3K in Q4 2025. 9 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Eastern Bank reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Eastern Bank sold 330 Viridian Therapeutics shares in Q2 2026, an estimated $6.46K.
  • Eastern Bank first reported a position in Viridian Therapeutics in Q4 2025 and held it in 2 quarters.
  • Eastern Bank's Viridian Therapeutics position peaked at $10.3K in Q4 2025.
  • 9 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Eastern Bank's 13F filing for Q2 2026, filed 1 Jul 2026.